Abstract-In the present study we tested the hypothesis whether an anglotensm AT, receptor-mediated stlmulatlon of the bradykmm (BK)/mtnc oxide (NO) system can account for the effects of AT1 receptor antagonism on aortlc cGMP described previously m SHRSP Adult SHRSP were treated for 4 hours with anglotensm II (ANG II) (30 rig/kg per mm IV) or vehicle (0 9% NaCl IV) Animals were pretreated with vehicle, losartan (100 mg/kg PO), PD 123319 (30 mg/kg IV), losartan plus PD 123319, lcatlbant (500 @g/kg IV), NG-mtro-L-argmme methyl ester (L-NAME, 1 mg/kg IV), or mmoxldll (3 mg/kg IV) Mean arterial blood pressure (MAP) was contmuouqly monitored over the 4-hour experlmental period, and plasma ANG II and aortlc cGMP were measured by RIA at the end of the study ANG II infusion over 4 hours raised MAP by about 20 mm Hg. Losartan alone or losartan plus ANG II '1s well as mmoxldll plus ANG II markedly reduced blood pressure when compared to vehicle-treated or ANG II-treated ammals, respectively Plasma levels of ANG II were increased 2-fold by ANG II mfuslon alone or by ANG II m combmallon with lcatlbant, L-NAME, or mmoxldll The increase m plasma ANG II levels was even more pronounced after losartan treatment Aortlc cGMP content was slgmficantly increased by ANG II, losartan, losartan plus ANG II, and mmoxldll plus ANG II by 60%, 45%, 68%, and 52%, respectively (P< 05) The effects of ANG II and of losartan plus ANG II on aortlc cGMP content were both blocked by cotreatment with the AT2 receptor antagonist PD 123319 Icatlbant and L-NAME abohshed the effects of ANG II on aortlc cGMP Our results demonstrate the followmg (1) ANG II increases aortlc cGMP by an AT, receptor-medlated action because the effect could be prevented by an AT1 receptor antagonist, (2) the effect of ANG II was not secondary to blood pressure increase because it remained under reduction of MAP with mmoxldll, (3) losartan increased aortlc cGMP most likely by increasing plasma ANG II levels with a subsequent stlmulatlon of AT, receptors, and (4) the effects of AT1 receptor stlmulatlon are mediated by BK and, subsequently, NO because they were abolished by B, receptor blockade as well as by NO synthase mhlbltlon of ANG II generation, but, m addition, also potentlate the effects of bradykmm (BK) by mhlbltlon of BK degradation ' Two major tools have been introduced m recent years to study the contnbutlon of BK to the cardiovascular actlons of ACE inhibitors first, the combined treatment with an ACE mhlbltor and with a specific BK B2 receptor antagonist such as lcatlbant, and second, the comparison of the effects of an ACE inhibitor with those of an AT, receptor antagonist which block the RAS without an interaction with kmm metabolism. With these approaches, several mvestlgators have demonstrated that a number of actions of ACE mhlbltors IS related to cardiovascular control can be blocked by B2 receptor antagonism and thus be related to kuuns ' For example, m a series of expenrnents our laboratory demonstrated that longterm treatment with ACE inhibitors improved cardiac function and metabohsm m hearts from SHRSP and preserved endothehal function as indicated by an increased vascular mtnc oxide (NO) production '-' All these effects could be prevented by B2 receptor antagonism, suggesting that they were BK mediated On lhe other hand, we observed that the AT, antagonist losartan produced stnkmgly similar effects as the ACE inhibitor under identical treatment condmons ' These results indirectly pointed that losartan, like the ACE inhibitor, can also interact with the kmm/NO system One possible mechanism for such an interaction could be related to a stlmulatlon of non-AT, receptors, particularly the AT, receptor, because losartan at therapeutic doses leaves the AT? receptor unopposed2*4 and because AT, receptor antagonism engenders an increase m plasma ANG II levels as a result of blockade of the AT, receptor-medlated negative feedback
T he renm-anglotensm system @AS), with Its effector peptide anglotensm II (ANG II), plays an Important role m the cardiovascular, electrolyte, and fluid homeostasls and has been implicated as an causative factor m the development of hypertension ' Inhibitors of the RAS such as anglotensmconverting enzyme (ACE) inhibitors and the nonpeptlde antagonists of the AT, receptor have been successfully mtroduced m the treatment of hypertension and other car&ovas-cular diseases AT, antagonists such as losartan interfere with the RAS by a specific blockade of the AT, receptor which mediates most of the known actions of ANG II 2-4 ACE mhlbltors, on the other hand, not only interfere with the RAS by mhlbltlon of ANG II generation, but, m addition, also potentlate the effects of bradykmm (BK) by mhlbltlon of BK degradation ' Two major tools have been introduced m recent years to study the contnbutlon of BK to the cardiovascular actlons of ACE inhibitors first, the combined treatment with an ACE mhlbltor and with a specific BK B2 receptor antagonist such as lcatlbant, and second, the comparison of the effects of an ACE inhibitor with those of an AT, receptor antagonist which block the RAS without an interaction with kmm metabolism. With these approaches, several mvestlgators have demonstrated that a number of actions of ACE mhlbltors IS related to cardiovascular control can be blocked by B2 receptor antagonism and thus be related to kuuns ' For example, m a series of expenrnents our laboratory demonstrated that longterm treatment with ACE inhibitors improved cardiac function and metabohsm m hearts from SHRSP and preserved endothehal function as indicated by an increased vascular mtnc oxide (NO) production '-' All these effects could be prevented by B2 receptor antagonism, suggesting that they were BK mediated On lhe other hand, we observed that the AT, antagonist losartan produced stnkmgly similar effects as the ACE inhibitor under identical treatment condmons ' These results indirectly pointed that losartan, like the ACE inhibitor, can also interact with the kmm/NO system One possible mechanism for such an interaction could be related to a stlmulatlon of non-AT, receptors, particularly the AT, receptor, because losartan at therapeutic doses leaves the AT? receptor unopposed2*4 and because AT, receptor antagonism engenders an increase m plasma ANG II levels as a result of blockade of the AT, receptor-medlated negative feedback 350 AT2 Receptors and the Kmm/NO System Selected Abbreviatmns and Acronyms ANG II = angmtensm II UK = bradykmm L-NAME = No-mtro-L-argmme methyl ester MAP = mean arterial blood pressure NO = mtnc oxide RAS = remn-angmtensm system SHRSP = stroke-prone spontaneously hypertenswe rats mhlbltlon of remn secretion m the kidney I(' In lme with this hypothesis are recent studies m bovme endothehal cells," isolated rat carotid arteries," canine microvessels from coronary artenes,13 rat aortlc stnps,14 and rat kldney,'s suggesting that ANG II or metabolltes of ANG II can stimulate NO production Furthermore, m a rat model of heart failure induced by myocardlal infarction, Lm et al'" demonstrated that the decrease m left ventricular end-dlastohc pressure and left ventricular systolic pressure induced by AT, receptor antagonism was blocked by an AT, antagonist and partially blocked by a B2 receptor antagomst Treatment was started 2 months after myocardlal infarction and was continued for another 2 months This study indicated that the effect of the AT, antagonist on cardiac function was dependent on the activation of AT2 receptors and was m part mediated by kmms
In the present study, we mvestlgated the effect of an acute oral treatment with the AT, antagonist losartan on aortlc cGMP content The hypothesis was that increased plasma ANG II concentrations during AT, receptor blockade can account for the effects of losartan on aortlc cGMP by stlmulatlon of unopposed AT2 receptors Therefore, we compared the effects of losartan with those of exogenously (mtravenously) applied ANG II alone In additional groups, we stimulated AT, receptors by mfuslon of ANG II dunng AT, receptor blockade and studled the effects of ANG II dunng AT? receptor blockade with the AT2 receptor antagonist PD 123319 In addition, we tested the hypothesis whether the stlmulatory effects of ANG II on aortlc cGMP are mediated by the BK/NO system by blockmg the BK B2 receptor with lcatlbant as well as by mhlbltlon of NO synthase with L-NAME Finally, to exclude the posslbllq that blood pressure increases induced by ANG II infusion may indirectly activate vasodllatory systems such as the NO/cGMP system m vascular endothehum, we also studied the effects of ANG II during condltlons of marked blood pressure reduction induced by treatment with the arterial vasodllator mmoxldll 
Experimental Protocol
Animals were randomly divided mto 11 groups Group 1 control (n= 14). rats were pretreated orally by gavage with dlstllled water (1 mL) or by an intravenous bolus mjectlon of phynologcal sahne (1 mL) followed by an intravenous mfuslon of physlologcal salme (1 mL/h) Group 2 ANG II 30 rig/kg per mm (n=25), rats were pretreated orally by gavage with d&led water (1 mL) or by IV bolus mjectlon of physlologlcal saline (1 mL) followed by an IV mfuslon of ANG II (30 rig/kg per mm) dissolved m physlologcal salme Group 3 Losartan (n=7), rats were pretreated orally by gavage (1 mL) with losartan (100 mg/kg) followed by an IV mfuslon of physlologcal salme (1 mL/h) Group 4 Losartan plus ANG II (n=7), rats were pretreated orally by gavage (1 mL) with losartan (100 mg/kg) followed by an IV mfuslon of ANG II (30 rig/kg per mm, 1 mL/h) Group 5 PD 123319 (n=8), rats were pretreated with PD 123319 (30 mg/kg per mL physlologlcal sahne, IV bolus mJectlon) followed by an IV mfuslon of physlologlcal salme (1 mL/h) Group 6 PD 123319 plus ANG II (n=B), rats were pretreated mtravenously with PD 123319 (30 mg/kg per mL physlologlcal sahne, IV bolus mJectlon) followed by an IV mfuslon of ANG II (30 rig/kg per mm, 1 mL/h) Group 7 Losartan plus PD 123319 plus ANG II (n=8), rats were pretreated orally by gavage with losartan (100 mg/kg) and mtravenously with PD 123319 (30 mg/kg per mL physlologlcal salme, IV bolus InJection) followed by an IV mfuslon of ANG II (30 rig/kg per mm, 1 mL/h) Group 8 L-NAME plus ANG II (n=lO), rats were pretreated mtravenously with L-NAME (1 mg/kg per 0 1 mL physlologtcal saline, IV bolus inJectIon) followed by an IV mfuslon of ANG II (30 rig/kg per mm, 1 mL/h) Group 9 Icatlbant plus ANG II (n=lO), rats were pretreated mtravenously with lcatlbant (0 5 mg/kg per 0 1 mL physlologcal salme, IV bolus Injection) followed by an IV mfuslon of ANG II (30 rig/kg per mm, 1 mL/h) (Fig  1) The AT, receptor antagonist PD 123319 did not alter MAP when compared with vehicle treated rats (data not shown) The blood pressure increase induced by mfuslon of 30 rig/kg per mm ANG II was not affected by cotreatment with either the AT2 antagonist PD 123319, the Bz receptor antagomst lcatlbant, or the NO-synthase inhibitor L-NAME (data not shown) In contrast, m SHRSP treated with ANG II (30 rig/kg per mm), MAP was markedly reduced when the animals were pretreated with the artenal vaso&lator mmoxldll (Fig I) A 4-hour infusion of ANG II at the lower dose of 3 rig/kg per mm did not alter MAP when compared with vehicle-treated rats (Fig I) Plasma ANG II Concentrations Plasma concentrations of ANG II were increased about 2-fold by ANG II mfuslon (30 rig/kg per mm) alone or by infusion of 30 rig/kg per mm ANG II m combmatlon with PD 1213319, lcatlbant, L-NAME, or mmoxldll (Fig 2) The increase m plasma ANG II levels was even greater after treatment with losartan alone (3 5-fold increase) or losartan m combmatlon with ANG II mfuston (2 6-fold increase) A of rats with losartan by 60% and 45%, respectively, when compared with vehicle-treated controls (Fig 3) The combmatlon of AT, blockade with losartan plus mfuslon of ANG II (30 rig/kg per mm) further increased aortlc cGMP content (68% mcrease when compared mth vehlcletreated controls) (Fig 3) The effects of ANG II mfuslon alone and of losartan plus ANG II infusion on aortlc cGMP content was abolished by blockade of AT, receptors with PD 123319 (Fig 3) The AT2 receptor antagomst alone had no effect on aortlc cGMP content (data not shown) Blockade of BK B2 receptors with lcatlbant as well as mhlbltlon of NO synthase with L-NAME markedly attenuated the effects of ANG II infusion on aortlc cGMP (Fig 3) The effect of ANG II infusion (30 rig/kg per mm) on aortlc cGMP was not secondary to the blood pressure increase induced by ANG II because a concomitant reduction of MAP by pretreatment with mmoxldll did not reduce the effect of ANG II (57% increase when compared to vehicle-treated rats) (Fig 3) A 4-hour mfuslon of ANG II at the lower dose of 3 rig/kg per mm did not slgmficantly alter aortlc cGMP content when compared with vehicle-treated rats (20% mcrease versus controls) (data not shown)
Discussion
The major finding of the present study 1s that ANG II stimulates the productlon of cGMP m the vascular wall by an AT2 receptor-dependent mechanism The effect of ANG II on aortlc cGMP was abolished by mhlbltlon of NO-synthase with L-NAME as well as by blockade of BK Bz receptors with lcatlbant These findings suggest that actlvatlon of NO synthase as well as stimulation of BK Bz receptors are both involved m the AT2 receptor-dependent actions ofANG II on aortlc cGMP
The increase m aortlc cGMP could be observed durmg condltlons of increased plasma ANG II concentrations resultmg from intravenous mfuslon of ANG II as well as durmg condltlons of increased production of endogenous ANG II as a result of AT1 receptor blockade Both mfuslon of ANG II at a rate of 30 rig/kg per mm as well as oral pretreatment with losartan at a dose of 100 mg/kg nearly doubled plasma ANG II concentrations Campbell et ali0 recently reported a 4-to &fold increase m ANG II plasma levels 6 to 24 hours after mtraartenal admmlstratlon of IO mg/kg losartan to SpragueDawley rats The effect of losartan on plasma ANG II levels may be even more pronounced after long-term treatment, as mhcated by a 25-fold increase m plasma ANG II after an 8-day IP admmlstratlon of 10 mg losartan twice dally '" Despite that the dose of 100 mg/kg losartan used m the present study 1s m the upper range for antlhypertenslve treatment m rats,lR the elevated blood pressure m SHRSP was markedly lowered but not normahzed Both the effect of ANG II as well as the effect of losartan on aortlc cGMP were blocked by AT2 receptor blockade with the selective AT, receptor antagonist PD 123319 This finding suggests that ANG II mediates its effects on vascular cGMP via stimulation of the AT, receptor m the vascular wall PD 123319 1s highly selective with a K, -12 nmol/L for the AT2 receptor and K, > 100 mol/L for the AT, receptor ")J' In the present study, the AT2 receptor antagonist PD 123319 was used at a dose of 30 mg/kg applied as an IV bolus inJection In a recent study, bolus mJectlons of PD 123319 at doses of 1 to 1000 g/kg followed by IV infusion of PD 123319 at concentrations of 1 to 1000 g/kg per mm for 1 hour produced plasma concentrations of the compound that ranged from 0 1 mol/L (lowest dose) up to 10 mol/L (highest dose) Treatment of rats with PD 123319 for 10 to 14 days with PD 123319 at a dose of 30 mg/kg per day applied by osmotic mmlpumps resulted m plasma levels m the range of 90 to 250 nmol/L " Expression of AT2 receptors m rat aorta (Sprague-Dawley rats) has been demonstrated by Vlswanathan et al" by bmdmg studies and quantitative autoradlography
Then results revealed a predominance of AT2 receptors m the aorta of fetus and young (2 weeks old) rats. In adult (8 weeks old) rats, approximately 30% of the receptors expressed m the aorta were AT2 This study also demonstrated that the number of ANG II receptors decreased with age, being 20 times lower m the adult rats compared with the fetus The data suggested a locahzatlon of AT1 receptors throughout the aortlc wall mcludmg the medial layer, although a locahzatlon of AT2 receptors to &stmct cell types was not possible Slmllar results were obtained by Song et alz3 m WKY and SHR. Endothehal cells denved from coronary arteries of SHR express AT, and AT,, receptors m a ratio of 80% to 20%.24 In rat aortlc endothehal cells, Pueyo et alz5 detected AT2 receptor expression m prohferatmg cells cultured without growth factors but not under normal culture condltlons, that 1s m the presence of growth factors These results confirm recent findings that growth factors downregulate AT2 receptor expression " Other studies failed to detect AT' as well as AT, receptors m endothehal cells denved from bovine aortaz7 or porcine arteries.*" Thus, the demonstration of ATI receptor expresslon may largely depend on the experimental condltlons. In the present study, we have not directly proven the expression of AT2 receptor m the aorta However, the fact that treatment with the specific AT2 receptor antagonist PD 123319 blocked the effects of ANG II alone and also the effects of the combmatlon of ANG II and losartan on aortlc cGMP content suggests the presence of AT,, receptors m the rat aorta under the condmons of our expenments
The finding that losartan can stimulate NO productron by an AT2 receptor-mediated and BK B,-dependent mechanism provides a direct explanation for results obtained m recent studies m SHRSP '79 In these studies, we treated SHRSP long-term with the ACE mhlbltor ramlpnl as well as with the AT' antagonist losartan (30 mg/kg per day) and determined the effect of treatment on carchac function and metabolism m ex vlvo isolated hearts and on vascular cGMP production The results revealed that the ACE mhlbltor improved cardiac function and metabolism and increased aortlc cGMP content, the effect being completely abolished by concomitant blockade of BK Bz receptors 6*7 The BK B2 receptor antagonist lcatlbant did not affect aortlc cGMP content after chronic apphcatlon usmg the same dose as m the present acute study On the other hand, the AT1 antagonist produced stnkmgly similar and, with regard to increases m aortlc cGMP content, even more pronounced effects as the ACE mhlbltor, suggesting a relatlonship between AT, antagonism and the kmm/NO system ') A number of recent studies have suggested the existence of a link between ANG II and the kmm/mtnc oxide system m various organs mcludmg the blood vessel wall, possibly medlated by the AT* receptor An mvolvement of a non-AT, receptor mechanism m the stimulation of guanylate cyclase m aortlc tissue has been described previously l4 ANG II at a concentration of 25 nmol/L stimulated cGMP production m incubated aortlc segments This effect was not affected by the AT1 antagonist losartan but could be blocked by mhlbltlon of soluble guanylare cyclase as well as by NO synthase mhlbluon with L-NAME l4 In bovine aortlc endothehal cells (BAEC), ANG II (10M7 to 10e4 mol/L) dose-dependently stimulated cGMP productton and enhanced the release of endogenous Several studies have demonstrated that the ANG II fragment ANG (l-7) can activate the kmm/NO system and potentlate the hypotenslve effects of BK m rats 3"3' Furthermore, ANG (l-7) has been shown to dilate canine and porcine coronary arteries by a NO and BK B2 receptor dependent mechanism The relaxation mduced by ANG (l-7) was not affected by AT, or AT2 receptor blockade '*Jo However, m one of these studle? the effects of ANG (l-7) seemed to be produced by yet unknown contammatlons of the ANG (l-7) batch provided by the manufacturer and were not confirmed with other ANG (l-7) batches 34
Seyedl et all3 recently demonstrated a NO production by measuring mtnte release of canme coronary mlcrovessels and canme large coronary artenes m response to a number of ANG peptldes including ANG II (10-s mol/L) and ANG (l-7) (10m5 mol/L) The effects of the ANG peptldes were blocked by an NO synthase mhlbltor and a BK B, receptor antagonist suggesting that the ANG-induced NO release was caused by an activation of local kmm production m the vessel wall Curiously, this effect could not be ascribed to distinct ANG receptor subtypes, because it was blocked by AT, as well as by AT, receptor antagonists Interestingly, a non-AT,, non-AT, anglotensm receptor with a high affinity for ANG (l-7) has been described m BAEC " However, unlike m the present study, there 1s no significant competltlon ofPD 123319 for the ANG (l-7) bmdmg site m BAEC."
In a mlcrodlalysls study, Slragy et alli demonstrated an increased cGMP concentration m the renal mterstltlal fluid m rats on normal sodium diet after ANG II apphcatlon This effect was blocked by concomitant admmlstratlon of the AT, antagonist PD 123319 In this study, PD 123319 as well as losartan alone had no effect on renal mterstltlal fluid cGMP content Furthermore, activation of the RAS by sodium depletion produced an increase m renal mterstltlal fluid cGMP This effect was not changed by losartan treatment, whereas PD 123319 caused a decrease m cGMP content, suggesting that the effect was AT2 mediated
In the present study, acute treatment with losartan at a dose of 100 mg/kg PO increased aortlc cGMP content 4 hours after drug apphcatlon In contrast, m a renm-dependent model of hypertension, le, m rats made hypertensive by coarctatlon of the aorta, losartan at a dose of 30 mg/kg IV did not change the cGMP content m the aorta 30 minutes after drug apphcatlon " Differences m the hypertension model (aortlc coarctatlon versus genetic hypertension)
or the time point of tissue coliectlon (0 5 hour versus 4 hours) may explam the dlfferenizes between both studies The finding that stimulation of AT, receptors produce NO generatlon m the vasculature suggests an mvolvement of AT, receptors m basal blood pressure mamtenance as well as a contnbutlon of AT, receptor stlmulatlon to the antlhypertgnslve actions of losartan However, at least during acute condltlons as m the present study, the AT, antagonist PD 123319 did not alter basal blood pressure when compared to vehlcletreated controls Furthermore, the blood pressure increase induced by ANG II was not further enhanced by concomitant AT, receptor blockade, suggesting that the AT? receptor mediated effect of ANG II on aortlc NO production does not contribute to the overall blood pressure effect Snnllar findings have been obtained by Levy et aP6 m normal Wlstar rats after 3 weeks of treatment with PD 123319 (30 mg/kg per day) alone or m combmatlon with ANG II (120 rig/kg per mm) In addition, m the present study, AT2 receptor blockade during coadmmlstratlon of losartan and ANG II did not attenuate the antihypertensive action of losartan but, m contrast, tended to further decrease blood pressure m this group However, several studies have suggested a depressor role of the AT2 receptor In anesthetized rats, ANG II and ANG III elicit a blphaslc arterial pressure response Losartan pretreatment blocked the pressor part of the response to ANG II and ANG III, whereas the depressor response became larger Combined blockade of AT, and AT2 receptors abolished all responses to ANG II and ANG III Although anesthesia might have influenced the outcome of this study, it suggested that the AT, receptor can mediate a depressor response to ANG II " It can be argued that the effect of ANG II on aortlc cGMP 1s secondary to the increase m blood pressure induced by ANG II, eg, by activation of counterregulatory active vasodllatory systems such as the kmm/NO system However, marked reduction of blood pressure by either losartan or the arterial vasodllator mmoxldll did not affect the ANG II induced increase m aortlc cGMP A second approach to exclude secondary effect of blood pressure was to infuse ANG II at a dose that did not alter basal blood pressure However, this low dose also failed to produce a significant increase m plasma ANG II and, consequently, failed to stimulate aortlc cGMP content
In conclusion, we demonstrated that losartan interacts with the kmm/NO system by stimulation of AT, receptors secondary to a losartan-induced increase m plasma ANG II concentrations The effects of losartan on aortlc cGMP were mlmlcked by intravenous ANG II infusion The actwatlon of AT2 receptors by ANG II resulted m a BK-dependent stlmulatlon of aortlc NO release with a subsequent generation of cGMP These AT2 receptor-dependent actions of losartan or ANG II do not seem to interfere with the acute effects of both substances on blood pressure but may help to explain some of the beneficial actlons of losartan on cardiovascular function and metabolism reported recently
